Octreotide vs Pasireotide
A long-acting somatostatin analog used to suppress GH and other hormones. A broader-spectrum somatostatin analog hitting more receptor subtypes. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Octreotide | Pasireotide | |
|---|---|---|
| Also known as | Sandostatin | Signifor |
| Type | Analog | Analog |
| Evidence | Established | Established |
| Family | Growth & repair | Growth & repair |
| Class | Somatostatin analog (cyclic octapeptide) | Somatostatin analog (cyclic hexapeptide) |
| Receptor | Somatostatin receptors (SSTR2 and SSTR5 preferential) | Somatostatin receptors (SSTR1, 2, 3, and 5) |
| Molecular weight | ~1,019.2 Da | ~1,047.2 Da |
| Half-life | ||
| Based on | Somatostatin | Somatostatin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Octreotide and Pasireotide?
- Octreotide is an engineered analog based on Somatostatin; Pasireotide is an engineered analog based on Somatostatin. Octreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential); Pasireotide signals at Somatostatin receptors (SSTR1, 2, 3, and 5).
- How do the half-lives of Octreotide and Pasireotide compare?
- The reported circulating half-life of Octreotide is ~1.5 h (subcutaneous; LAR depot ~monthly); Pasireotide is ~12 h. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Octreotide the same as Sandostatin?
- Sandostatin is a brand name of Octreotide. This comparison describes the molecules, not branded products.
Prefer the other order? Pasireotide vs Octreotide. Or open the interactive comparison tool to add more molecules.